Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers.

ABSTRACT:

Unlabelled

Large collections of annotated cancer cell lines are powerful tools for precisely matching targeted drugs with genomic alterations that can be tested as biomarkers in the clinic. Whether these screening platforms, which utilize short-term cell survival to assess drug responses, can be applied to precision radiation medicine is not established. To this end, 32 cancer cell lines were screened using 18 targeted therapeutic agents with known or putative radiosensitizing properties (227 combinations). The cell number remaining after drug exposure with or without radiation was assessed by nonclonogenic assays. We derived short-term radiosensitization factors (SRF2Gy) and calculated clonogenic survival assay-based dose enhancement factors (DEFSF0.1). Radiosensitization was char

SUBMITTER: Liu Q 

PROVIDER: S-EPMC4410013 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature